Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

Response to immune checkpoint therapy can be associated with a high mutation burden, but other mechanisms are also likely to be important. We identified a patient with metastatic gastric cancer with meaningful clinical benefit from treatment with the anti–programmed death–ligand 1 (PD-L1) antibody a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Natl Cancer Inst
Päätekijät: Panda, Anshuman, Mehnert, Janice M, Hirshfield, Kim M, Riedlinger, Greg, Damare, Sherri, Saunders, Tracie, Kane, Michael, Sokol, Levi, Stein, Mark N, Poplin, Elizabeth, Rodriguez-Rodriguez, Lorna, Silk, Ann W, Aisner, Joseph, Chan, Nancy, Malhotra, Jyoti, Frankel, Melissa, Kaufman, Howard L, Ali, Siraj, Ross, Jeffrey S, White, Eileen P, Bhanot, Gyan, Ganesan, Shridar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Brief Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6658862/
https://ncbi.nlm.nih.gov/pubmed/29155997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx213
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia